OASMIA PHARMACE/ADR (OASM) Raised to “Buy” at ValuEngine
ValuEngine upgraded shares of OASMIA PHARMACE/ADR (NASDAQ:OASM) from a hold rating to a buy rating in a research report report published on Tuesday morning.
NASDAQ OASM opened at $4.93 on Tuesday. OASMIA PHARMACE/ADR has a fifty-two week low of $0.85 and a fifty-two week high of $5.70.
OASMIA PHARMACE/ADR (NASDAQ:OASM) last posted its earnings results on Friday, August 31st. The company reported ($0.06) earnings per share for the quarter. OASMIA PHARMACE/ADR had a negative net margin of 3,528.00% and a negative return on equity of 32.95%. The company had revenue of $0.02 million for the quarter.
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The company's approved products include Paclical/Apealea, a water-soluble formulation of XR17 and paclitaxel to treat cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs.
Recommended Story: Yield Curve
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OASMIA PHARMACE/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OASMIA PHARMACE/ADR and related companies with MarketBeat.com's FREE daily email newsletter.